» Articles » PMID: 20070106

Physicochemical Space for Optimum Oral Bioavailability: Contribution of Human Intestinal Absorption and First-pass Elimination

Overview
Journal J Med Chem
Specialty Chemistry
Date 2010 Jan 15
PMID 20070106
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh). In this study, using a database comprised of Fa, Fg, Fh, and F values for 309 drugs in humans, an analysis of the interrelation of physicochemical properties and the individual parameters was carried out in order to define the physicochemical space for optimum human oral bioavailability. Trend analysis clearly indicated molecular weight (MW), ionization state, lipophilicity, polar descriptors, and free rotatable bonds (RB) influence bioavailability. These trends were due to a combination of effects of the properties on Fa and first-pass elimination (Fg and Fh). Higher MW significantly impacted Fa, while Fg and Fh decreased with increasing lipophilicity. Parabolic trends were observed for bioavailability with polar descriptors. Interestingly, RB has a negative effect on all three parameters, leading to its pronounced effect on bioavailability. In conclusion, physicochemical properties influence bioavailability with typically opposing effects on Fa and first-pass elimination. This analysis may provide a rational judgment on the physicochemical space to optimize oral bioavailability.

Citing Articles

Hydrogels and Nanogels: Pioneering the Future of Advanced Drug Delivery Systems.

Delgado-Pujol E, Martinez G, Casado-Jurado D, Vazquez J, Leon-Barberena J, Rodriguez-Lucena D Pharmaceutics. 2025; 17(2).

PMID: 40006582 PMC: 11859140. DOI: 10.3390/pharmaceutics17020215.


The Use of Tissue Concentrations of Biological and Small-Molecule Therapies in Clinical Studies of Inflammatory Bowel Diseases.

Bayoumy A, Derijks L, Oldenburg B, de Boer N Pharmaceutics. 2025; 16(12.

PMID: 39771479 PMC: 11676153. DOI: 10.3390/pharmaceutics16121497.


Development of a novel gut microphysiological system that facilitates assessment of drug absorption kinetics in gut.

Imaoka T, Onuki-Nagasaki R, Kimura H, Tai K, Ishii M, Nozue A Sci Rep. 2024; 14(1):29921.

PMID: 39622870 PMC: 11612460. DOI: 10.1038/s41598-024-80946-6.


Clinical Trial Data-Driven Risk Assessment of Drug-Drug Interactions: A Rapid and Accurate Decision-Making Tool.

Yuan T, Bi F, Hu K, Zhu Y, Lin Y, Yang J Clin Pharmacokinet. 2024; 63(8):1147-1165.

PMID: 39102093 DOI: 10.1007/s40262-024-01404-0.


Exploration of Abiraterone acetate loaded Nanostructured lipid carriers for bioavailability improvement and circumvention of fast-fed variability.

Shah S, Famta P, Vambhurkar G, Sharma A, Mourya A, Srinivasarao D Drug Deliv Transl Res. 2024; 15(3):1074-1091.

PMID: 38995610 DOI: 10.1007/s13346-024-01657-z.